109 related articles for article (PubMed ID: 33328763)
1. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
[TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of gemcitabine plus S-1
Zhu Z; Tang H; Ying J; Cheng Y; Wang X; Wang Y; Bai C
Cancer Biol Med; 2023 Aug; 20(10):765-78. PubMed ID: 37646237
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
Chang C; Li X; Cheng K; Cai Z; Xiong J; Lv W; Li R; Zhang P; Cao D
Oncologist; 2023 Jul; 28(7):e575-e584. PubMed ID: 35930304
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and resource utilization of
Braiteh F; Patel MB; Parisi M; Ni Q; Park S; Faria C
Cancer Manag Res; 2017; 9():141-148. PubMed ID: 28461766
[TBL] [Abstract][Full Text] [Related]
9.
Tabernero J; Kunzmann V; Scheithauer W; Reni M; Shiansong Li J; Ferrara S; Djazouli K
Onco Targets Ther; 2017; 10():591-596. PubMed ID: 28203092
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
[TBL] [Abstract][Full Text] [Related]
11. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
[TBL] [Abstract][Full Text] [Related]
12. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
13. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of
Mudad R; Patel MB; Margunato-Debay S; Garofalo D; Lal LS
Lung Cancer (Auckl); 2017; 8():179-190. PubMed ID: 29089791
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Ko AH; Kim KP; Siveke JT; Lopez CD; Lacy J; O'Reilly EM; Macarulla T; Manji GA; Lee J; Ajani J; Alsina Maqueda M; Rha SY; Lau J; Al-Sakaff N; Allen S; Lu D; Shemesh CS; Gan X; Cha E; Oh DY
Oncologist; 2023 Jun; 28(6):553-e472. PubMed ID: 36940261
[TBL] [Abstract][Full Text] [Related]
16. Low-dose gemcitabine plus nab-paclitaxel
Kamata K; Imai H; Matsumoto H; Yamashita Y; Kato T; Nishi K; Omoto S; Minaga K; Yamao K; Hyodo T; Im SW; Hara A; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Ueshima K; Chiba Y; Takenaka M; Watanabe T; Kitano M; Kudo M
JGH Open; 2023 Sep; 7(9):659-666. PubMed ID: 37744711
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Zhang W; Du C; Sun Y; Yang L; Cui C; Jiang Z; Wang C; Wang J; Zhou A
Cancer Chemother Pharmacol; 2018 Oct; 82(4):655-660. PubMed ID: 30054709
[TBL] [Abstract][Full Text] [Related]
19. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
Chiang NJ; Chang JY; Shan YS; Chen LT
Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
